206 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
University of Bari Aldo Moro
Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptora/d (PPARa/d) dual agonistic activity.
The University of Tokyo
PPAR Agonists, Compounds, Pharmaceutical Compositions, and Methods of Use Thereof.
Temple University
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.
Bristol-Myers Squibb
Syringaresinol induces mitochondrial biogenesis through activation of PPARß pathway in skeletal muscle cells.
Korea University
Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptorß/d agonists with neuroprotective activity.
Texas Tech University Health Sciences Center
SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.
Central Pharmaceutical Research Institute
Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.
Max Planck Institute For Molecular Genetics
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor¿ Modulators.
Goethe-University Frankfurt
Synthesis of 5-trifluoromethyl-2-sulfonylpyridine PPARß/d antagonists: Effects on the affinity and selectivity towards PPARß/d.
University of Oslo
Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor¿/d agonists.
Sookmyung Women'S University
Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
Goethe-University Frankfurt
Synthesis, biological evaluation and molecular modeling studies of the PPARß/d antagonist CC618.
University of Oslo
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).
Glaxosmithkline
Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-a (PPAR-a) agonists.
National Institute of Pharmaceutical Education and Research (NIPER)
Structural development studies of PPARs ligands based on tyrosine scaffold.
Universit£&Quot;G. D'Annunzio&Quot
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.
Phenex Pharmaceuticals
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
Goethe-University Frankfurt
Identification of the first potent, selective and bioavailable PPARa antagonist.
Inception Sciences
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Glaxo Wellcome Research and Development
Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR¿ agonists.
Glaxosmithkline
Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor¿.
Helmholtz Centre For Infection Research
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
The University of Sydney
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.
Pfizer
Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.
Glaxosmithkline
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.
Glaxosmithkline
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
Istituto Tumori&Quot;Giovanni Paolo Ii&Quot
Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors.
Zafes/Liff/Osf Goethe-University Frankfurt
Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-¿B activation and PPAR transcriptional activity.
Chungnam National University
Design, synthesis and in vitro evaluation of a series ofa-substituted phenylpropanoic acid PPAR¿ agonists to further investigate the stereochemistry-activity relationship.
Okayama University
Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
Trinity College
Activity landscape modeling of PPAR ligands with dual-activity difference maps.
Universidad Nacional Aut£Noma De M£Xico
Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptord agonists as potent anti-obesity agents in vivo.
Seoul National University
Total synthesis and dual PPARa/¿ agonist effects of amorphastilbol and its synthetic derivatives.
Korea Institute of Science and Technology
(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARß/d-selective ligand with inverse agonistic properties.
Philipps University
Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR)¿ Agonists.
Takeda Pharmaceutical
Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
Chungnam National University
Identification of diaryl ether-based ligands for estrogen-related receptora as potential antidiabetic agents.
Johnson & Johnson Pharmaceutical Research and Development
Design, synthesis, and structural analysis of phenylpropanoic acid-type PPAR¿-selective agonists: discovery of reversed stereochemistry-activity relationship.
Okayama University
Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.
Johnson & Johnson Pharmaceutical Research and Development
Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Nippon Shinyaku
SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
University of Tokyo
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Nippon Shinyaku
Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.
Johnson & Johnson
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Eli Lilly
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
The Scripps Research Institute
Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
The University of Tokyo
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor¿ (PPAR¿) modulators.
Merck Research Laboratories
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR)¿ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
Takeda Pharmaceutical
Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.
Kyorin Pharmaceutical
Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.
University of Oslo
Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.
The University of Tokyo
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.
The University of Tokyo
Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR)a-selective agonists.
Okayama University
Biological evaluation of novel benzisoxazole derivatives as PPARd agonists.
Nippon Chemiphar
Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARd agonists.
Astrazeneca R&D Charnwood
Synthesis of a novel human PPARd selective agonist and its stimulatory effect on oligodendrocyte differentiation.
Nippon Chemiphar
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
Zydus Research Centre
Selective peroxisome proliferator-activated receptord isosteric selenium agonists as potent anti-atherogenic agents in vivo.
Seoul National University
A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.
Seoul National University
Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR)d-selective partial agonists by disruption of molecular planarity/symmetry.
The University of Tokyo
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
Bristol-Myers Squibb
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
The Genomics Institute of The Novartis Research Foundation
Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) delta selective antagonists.
The University of Tokyo
Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.
Glaxosmithkline
Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists.
Goethe-University Frankfurt
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
F. Hoffmann-La Roche
Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
National Health Research Institutes
Selective, potent PPARgamma agonists with cyclopentenone core structure.
Universidade De Vigo
Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
University of Innsbruck
Highly functionalized 7-azaindoles as selective PPAR gamma modulators.
Merck Research Laboratories
Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.
The University of Tokyo
CoMFA analysis of dual/multiple PPAR activators.
National Institute of Pharmaceutical Education and Research
Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.
Glaxosmithkline
Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.
Eli Lilly
Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.
Guangdong Pharmaceutical University
Structure-Activity Relationships of Truncated 1'-Homologated Carbaadenosine Derivatives as New PPARγ/δ Ligands: A Study on Sugar Puckering Affecting Binding to PPARs.
Seoul National University
Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.
Re&D Vufb
Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
Kowa
Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
University of Tokyo
Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.
Nagoya City University
Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARdelta agonists.
Johnson and Johnson Pharmaceutical Research and Development
Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
Pfizer
Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
Pfizer
Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists.
Guangdong Pharmaceutical University
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
Novo Nordisk
Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases.
China Pharmaceutical University
Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure.
Shionogi
Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists.
Shionogi
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.
Sichuan University
Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.
Bayer Pharmaceuticals
Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview.
University Clinic Hospital of Valencia
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Institute of Mit and Harvard
Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
University of Health Sciences and Pharmacy
Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
National Health Research Institutes
Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
Eli Lilly
Discovery of Pan-peroxisome Proliferator-Activated Receptor Modulators from an Endolichenic Fungus,
Seoul National University
3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1.
The Genomics Institute of The Novartis Research Foundation
Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.
F. Hoffmann-La Roche
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
Universit£?Degli Studi Di Bari "Aldo Moro
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
University of Toronto
1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists.
The Genomics Institute of The Novartis Research Foundation
Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
Guangdong Pharmaceutical University
Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
Southern Medical University Biomedical Research Center
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
Guangdong Pharmaceutical University
Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
National Health Research Institutes
Design and synthesis of potent and subtype-selective PPARalpha agonists.
Merck Research Laboratories
Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.
National Health Research Institutes
Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
University of Tokyo
Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents.
Novartis Institutes For Biomedical Research
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
Merck Research Laboratories
Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
Shionogi
(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.
Merck Research Laboratories
Design, Synthesis, and Biological Activity of l-1'-Homologated Adenosine Derivatives.
Chonnam National University
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists
Broad Institute of Mit and Harvard
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
Eli Lilly
Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
China Pharmaceutical University
A Photohormone for Light-Dependent Control of PPARα in Live Cells.
Goethe-University Frankfurt
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
Research Institute of Tsinghua University
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
University of Toledo College of Pharmacy and Pharmaceutical Sciences
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
Merck Research Laboratories
Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
Eli Lilly
Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Guangdong Pharmaceutical University
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Bristol-Myers Squibb
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
Eli Lilly
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
Novo Nordisk
Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists.
Merck Research Laboratories
Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease.
City of Hope National Medical Center
Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
China Pharmaceutical University
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
Kyorin Pharmaceutical
5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.
Merck Research Laboratories
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Lilly Research Laboratories
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
Merck Research Laboratories
Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.
Glaxosmithkline
Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.
Merck Research Laboratories
Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.
Novo Nordisk
Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).
Mitobridge
Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators.
Seoul National University
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
Tes Pharma
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Novo Nordisk
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
Glaxosmithkline
Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.
Glaxosmithkline
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
Seoul National University
Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta.
Glaxosmithkline
Design and Structural Optimization of Dual FXR/PPARδ Activators.
Goethe University Frankfurt
Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective.
Daegu-Gyeongbuk Medical Innovation Foundation
Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.
Glaxosmithkline
Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPARδ modulators.
Mitobridge
Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ.
Seoul National University
Discovery of Second Generation RORγ Inhibitors Composed of an Azole Scaffold.
Kyoto Prefectural University of Medicine
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
University of Chieti "G. D.Annunzio
Structure-activity relationship studies of non-carboxylic acid peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
The University of Tokyo
Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
Guangdong Pharmaceutical University
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
Goethe University Frankfurt
The PPARs: from orphan receptors to drug discovery.
Glaxo Wellcome Research & Development
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
Glaxo Wellcome Research & Development
A Selective Modulator of Peroxisome Proliferator-Activated Receptor γ with an Unprecedented Binding Mode.
Goethe-University Frankfurt
Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders.
University of Oklahoma
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Terns Pharmaceuticals
Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies.
Inception Sciences
Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Boryung Pharmaceuticals
Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.
Wuxi Apptec (Shanghai) Co.
Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
Okayama University
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Guangdong Pharmaceutical University
Synthesis and evaluation of 4-cycloheptylphenols as selective Estrogen receptor-β agonists (SERBAs).
Marquette University
Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.
Daegu-Gyeongbuk Medical Innovation Foundation
Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions.
University of Oklahoma
Novel highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulators with pharmacokinetic properties suitable for once-daily oral dosing.
Mitobridge
Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
Janssen Research and Development
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Inventiva
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptorα/δ (PPARα/δ) dual agonists.
The University of Tokyo
Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
Universite De Lille 2 Droit Et Sante
2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
Bayer Pharma Aktiengesellschaft
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
Merck Sharp & Dohme
Heterocyclic derivatives and their use in the treatment of neurological disorders
Novartis
2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit.
Alcon Research